JANX009 / Janux Therapeutics - LARVOL DELTA

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Businesswire) - "Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023; PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023."

IND • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Bifunctional Tumor Activated Immunomodulator (TRACIr) Targeting PD-L1 And CD28 Is a Potent Enhancer of T Cell-Mediated Anti-Tumor Activity (SITC 2022) - "However, the first phase 1 clinical trial of the CD28 agonistic antibody TGN1412 failed due to an unexpected and rapid systemic proinflammatory cytokine response...PD-L1 blocking activity was comparable with atezolizumab, avelumab, nivolumab, and pembrolizumab...Finally, TRACIr was well tolerated in NHPs at high doses and exhibited half-life extended pharmacokinetics. Conclusions Preclinical activity and safety profiles of PDL1xCD28 TRACIr support its further development as an attractive bifunctional T cell modulator."

Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (Businesswire) - "We anticipate providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023, submitting an IND for our EGFR-TRACTr (JANX008) in the second half of 2022, and selecting a development candidate for our TROP2-TRACTr in 2023. In addition, we selected a PD-L1xCD28 TRACIr development candidate in the fourth quarter of 2021 and we expect to submit an IND for this product candidate (JANX009) in 2023."

IND • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (Businesswire) - "TRACTr candidate pipeline advancing with a Phase 1 clinical trial for JANX007 expected to initiate in 2H 2022 and an IND submission for EGFR-TRACTr (JANX008) in 2H 2022....Janux expects to submit an IND application to the FDA for its PD-L1xCD28 TRACIr in 2023."

IND • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (Businesswire) - "Janux expects to submit an IND application to the FDA for its PD-L1xCD28 TRACIr in 2023....Janux expects to submit an IND application to the FDA for its EGFR-TRACTr (JANX008) in the second half of 2022."

IND • Oncology • Solid Tumor